Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) VP Tami Tillotson Martin sold 5,000 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $32.98, for a total value of $164,900.00. Following the completion of the sale, the vice president now owns 87,220 shares in the company, valued at approximately $2,876,515.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Supernus Pharmaceuticals Price Performance
NASDAQ SUPN traded down $0.65 during trading hours on Friday, reaching $32.16. 652,235 shares of the stock traded hands, compared to its average volume of 416,375. The stock has a 50 day simple moving average of $29.11 and a two-hundred day simple moving average of $29.79. Supernus Pharmaceuticals, Inc. has a 1 year low of $23.15 and a 1 year high of $34.50. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.00 and a quick ratio of 1.69. The company has a market cap of $1.72 billion, a price-to-earnings ratio of 24.74 and a beta of 1.04.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.15). Supernus Pharmaceuticals had a net margin of 12.20% and a return on equity of 9.05%. The firm had revenue of $170.10 million for the quarter, compared to analysts’ expectations of $164.23 million. During the same quarter in the previous year, the business earned $0.43 EPS. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. On average, analysts predict that Supernus Pharmaceuticals, Inc. will post 1.64 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on SUPN shares. StockNews.com upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 18th. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, April 18th.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.